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Structured summary 
Aims: This study investigates paediatric drug dosage guidelines with the aim of investigating their 
agreement with body surface area (BSA) scaling principles. 
Methods: 454 drug dosage guidelines listed in the AMH-CDC 2015 were examined. Data extracted 
included the administration, frequency and dose per age bracket from  0-18 years. Drug treatments were 
categorized as follows: 1) The same dose recommendation in milligrams per kilogram (mg/kg) for all 
age/weights; 2) Change in the mg/kg dosing according to age/weight; 3) Change in dose in mg 
according to age/weight; 4) Change from mg/kg dosing to a dose in mg according to age/weight; 5)  
The same recommendation for all age/weight groups in mg or 6) BSA dosing. Example drugs were 
selected to illustrate dose progression across ages. 
Results: Most drug treatments (63%) have the same mg/kg dose for all age/weight groups, 14%  are 
dosed in mg/kg across all ages with dose changes according to age/weight, 13% were dosed in mg 
across all ages with dose changes, 10% switched from mg/kg to a set dose in mg, 4.2% have the same 
dose in mg for all age and weight groups and 2.2%  are dosed according to BSA. 
Conclusions:  
Paediatric dosage guidelines are based on weight-based formulas, available dosing 
formulations, and prior patterns of use. Substantial variation from doses predicted by BSA scaling are 
common, as are large shifts in recommended doses at age thresholds. Further research is required to 
determine if better outcomes could be achieved by adopting biologically based scaling of paediatric 
doses.   
 
 
What’s Known on This Subject 
 Minimal pharmacokinetic understanding in children has led to arbitrary dosing across the 
paediatric age range 
 Arbitrary dosing may consequent in unwanted side effects due to overdose, or lack of effect 
due to underdosing.  
 
What This Study Adds 
 Recommended paediatric doses appear to be based on simple formulas (such as mg/kg), 
available dosing formulations, and prior patterns of use.  
 Two or more-fold variation from doses predicted by allometric scaling are common, as are 
arbitrary large shifts in recommended doses at age thresholds. 
 
  
Introduction 
In an ideal world, pharmacokinetic and pharmacodynamic profiles for every paediatric drug 
would be established and the results would inform dosage guidelines. Unfortunately, for most 
paediatric drugs these profiles have not been established leaving a remarkable lack of empirical data 
to guide dose selection for people under 18 and great variability in quantity and quality of information 
supporting dose recommendations. Many dosage guidelines rely on the extrapolation of data from 
adults and animals in conjunction with application of various scaling principles. Often this makes the 
assumption that children are equivalent to ‘small adults’ physiologically, physicochemically and 
biochemically, disregarding the impact of ontogeny on the pharmacokinetics, safety and efficacy of 
the drugs(1)..  Clinicians are aware however, that development of paediatric drug dosing requires a 
thorough and rigorous consideration of the effect of developmental changes in medication response, 
and the large differences in physiological characteristics between children and adults, most notably 
variation in body composition, differential liver and kidney functioning and drug-metabolizing 
capacity  (2, 3). It is noteworthy that there are also considerable differences within these parameters 
across the paediatric age spectrum.  For example, some metabolizing enzymes are only a fraction of 
adult levels during infancy leading to decreased drug clearance and dosing requirements in this age 
group (4-6). 
Allometric scaling approaches dosage such that dose for children is a partial adult dose, 
dependent on variable factors of age, height and weight (2).  Recommended doses are provided, with 
paediatricians left to determine a more appropriate dose on a patient case-by-case. Determining doses 
based on body surface area (BSA; mg/m2), is one such favoured allometric scaling approach. BSA can 
be used as a surrogate for drug metabolism - based on the premise that BSA is proportional to heat 
loss from the body (7). Furthermore, many other physiological parameters are associated with BSA, 
such as tissue volume, blood flow and organ size (8). Dosing based on BSA is not without its 
limitations. It assumes that adults and children are geometrically similar. While this may be true for 
children, term and preterm neonates do not have similar morphology to adults, for example, their 
heads are relatively bigger and body trunks relatively larger. The implication of this is that scaled 
clearance in infants may be underestimated leading to the underestimation of maintenance dose (9). 
Using gestational rather than chronological age may allow optimal dosing that accounts for neonate 
ontogenesis, although this methodology is not widely adopted and dosage guidelines rarely include 
preterm newborns. Furthermore, BSA dosing is also prone to errors, because of the complexity of 
mathematical calculations. Other allometric scaling approaches include the ⅔ power surface area 
model, using a fixed exponent of 0.67 (1, 10) and the ¾ power surface area model, using a fixed 
exponent of 0.75. (11).  
Weight based dosing assumes there is a linear relationship between weight and dose (7), 
though drug clearance is better correlated with lean body weight or fat free weight  than total body 
weight (12) and there is currently no bedside method of estimating lean body weight in order to better 
estimate dose. This is particularly of significance in obese children. However, drug dosage guidelines 
still are often delivered in terms of mg/kg or as a set dose and how well this reflects a desirable BSA 
scaling method is not immediately evident. Commonly a switch between the dosing regimens (set 
dose to mg/kg or vice versa) will occur at a particular age cut off somewhere between infancy and 
childhood, or childhood and adolescence. While these age cut-offs are designed to account for 
developmental changes in drug metabolism, in the real world the dosing regimen changes seem rather 
arbitrary and titration between one developmental stage and another is not apparent. Considering 
paediatric dose recommendations –whether as a set dose or mg/kg - in their equivalent weight and 
height (mg/m2) dosage, offers the opportunity to assess the consistency across age groups.  
Furthermore, when used in children a significant proportion of medications are used on an off-
label basis (13, 14). A 10-week study of a neonatal intensive care unit reported 47% of prescriptions to 
be off-label (15). Further, a retrospective study of paediatric inpatients in an Australian teaching hospital 
reported 31.8% of prescriptions to be off-label (13) and a one year study including Australian 
emergency department, inpatient and outpatient clinics at a paediatric teaching hospital reporting off-
label use of medications to be at around 25.7% (16). The significant proportion of off-label medication 
use highlights the need for consistent, evidence-based research to guide dosing regimens in paediatric 
patients.  
In the absence of the pharmacodynamic and pharmacokinetic studies required to inform optimal 
dosing in children, clinicians rely on national formularies to assist prescribing practices. In Australia, 
the formulary used for children is the Australian Medicine’s Handbook Children’s Dosing Companion 
(AMH-CDC) (17). The resource, like all national formularies, is guided by the best available evidence 
and undergoes a rigorous editorial and expert review process to formulate its recommendations. Given 
that the evidence base for dosing simply does not exist for most drugs in children, allometric scaling 
principles are considered the “next best” and therefore should be present in dosing guidelines. Using 
the AMH-CDC, this study investigates dosage guidelines for the paediatric population.  
This study aimed to identify various dosage inconsistencies and discontinuities across the age 
range thereby highlighting the need for research and development of allometric models for paediatric 
dosing. Notwithstanding the priority for complete pharmacokinetic data and established dosing 
guidelines. 
 
Methods 
Data extraction 
Information on all 674 dosage guidelines listed in the AMH-CDC 2015 were extracted and collated in 
Microsoft Excel (2016). Dosing data extracted from the guide for each drug indication included the 
administration, frequency and dose per age bracket from birth to 18 years (mg/kg). The average 
weights and heights for each age group as specified in the AMH-CDC were used. We excluded 
medications that are not dosed in a way that makes sense to apply dose scaling principles. This 
includes drugs with the following administration routes: eye, topical, nasal, inhalant, ear, hair, intra-
tracheal, intra-articular. For the same reason we have excluded drugs with no specific regimen. In 
order to examine dosing guidelines for medications that can be used during most of the paediatric 
lifespan we have also excluded medications contraindicated in children under 6 and medications only 
used in neonates (see Figure 1 for inclusion flow chart).  
 
From the excel workbook, the included drug treatments were examined in terms of the 
progression of dosing guidelines from birth until age 18. Based on our observations the following dosing 
groups were determined as the best way to categorize the drug dosing patterns across all included 
medicines: 
1. The same dose recommendation for all age or weight groups in milligram/kilogram 
(mg/kg); 
2. Change in the mg/kg dosing according to age or weight; 
3. Change in the set dose in milligrams (mg) according to age or weight;  
4. Change from mg/kg dosing regimen to a set dose in mg according to age or weight;  
5. The same dose recommendation for all age or weight groups in mg; or 
6. Drugs dosed according to BSA (mg/m2). 
To ensure that these dosing categories were not only a reflection of Australian guidelines the 
British National Formulary (BNF) for Children (18) was also checked. For each included drug in the 
CDC we searched the drug recommendations in the BNF when indicated for the same or equivalent 
indication, administration route and formulation. The BNF doses for these drugs were then examined 
and categorised according to the same dosing groups determined for the CDC. 
In the current analysis we have used BSA as an example allometric scaling principle. BSA 
makes similar adjustments to the dose as other scaling principles such as exponent 0.75 and 0.67. This 
similarity is demonstrated in Figure 2. To illustrate differences in BSA across the paediatric lifespan, 
we arbitrarily selected example drugs from the CDC from dose group categories 1 - 4. Category 5 was 
not graphed as these drugs did not change dose recommendation according to age or weight and 
category 6 was not graphed as it includes medications already dosed according to BSA. For each 
selected drug the minimum and maximum dosage in mg, mg/kg and the equivalent, milligrams per 
body surface area (mg/m2) for each age group was calculated using the average weights and heights 
per age bracket provided in the AMH-CDC. Body surface area was calculated using the Mosteller 
formula as follows:  
BSA =  
√(weight (kg) × height (cm)
3600
 
The minimum and maximum mg/kg doses were then converted to GraphPad Prism Version 6 
for Windows (GraphPad Software, La Jolla California USA), where graphs were plotted, providing a 
function to observe the trends progressing through age, birth to 17, average weight, 3.3kg to 62kg and 
average height, 50cm to 160cm. Discontinuities were defined as a disruption in mg/m2 dosage across 
age groups as a result of change in dose from mg/kg to a set dose or vice versa. As well as cross-
referencing to the BNF the selected drugs were also compared to the American Hospital Formulary 
Service (AHFS)(19)  to assess the international similarities and differences in dosing recommendations. 
Nomenclature of Ligands  
Key ligands in this article are hyperlinked to corresponding entries in 
http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to 
PHARMACOLOGY(20). 
 
Results  
There were 465 included drug treatments. Close to two-thirds of the drug treatments (n = 289, 
63%) had the same dose mg/kg dose for all age and weight groups (dose category 1), 14% (n = 65) of 
drug treatments were dosed in mg/kg across all ages but the dose changed one or more times according 
to changes in weight or age (dose category 2), 13% (n = 61) of drug treatments were dosed in mg across 
all ages but the set dose changed one or more times according to changes in weight or age (dose category 
3), 10% (n = 48) of drug treatments switched from dosing according to mg/kg to a set dose in mg 
according to changes in weight or age (dose category 4), 4.2% (n=19) had the same dose in mg for all 
age and weight groups and the remaining 2.2% (n = 10) were dosed according to BSA. All included 
CDC drug treatments and their dose group categories are shown in Supplementary Material 1. Of the 
454 included drug treatments from the CDC, 325 were also present in the BNF with equivalent 
administration routes, formulations and indications. Over a third of those (n = 126, 38.8%) fit into dose 
category 1, 14.1% (n=46) in dose category 2, 12.6% (n = 41) in dose category 3, 27.4% (n = 89) in dose 
category 4, 3.7% (n = 12) in dose category 5 and the remaining 3.4% in dose category 6. Table 1 details 
the example drug treatments chosen from categories 1 - 4. For each example drug treatment, figures 2 
– 9 show the respective varying dosage recommendations across the age range with the equivalent 
mg/m2 dosage.  
Figure 3, dexamethasone, is an example from CDC dosing category 1. As can be seen in the 
figure, it is dosed at a constant range of 0.15mg/kg-0.3mg/kg, which is equivalent to almost a 10-fold 
increase in total mg across the age range and a doubling of the mg/m2. The maximum dose of 
dexamethasone recommended in the BNF is slightly lower than that of the AMH-CDC (0.45mg/kg vs. 
0.60mg/kg, respectively). Figure 4, digoxin, is an example from dosing category 2. The figure shows a 
stepwise decrease in the mg/kg dosing through the age groups which is equivalent to mg/m2 fluctuations 
between 0.22 and 0.12. Dosing of digoxin is fairly similar between AMH-CDC, BNF and AMH, except 
that the BNF recommends a fixed dose of 62.5 - 250 µg between 10 – 17 years. Figure 5, desmopressin, 
is an example from dosing category 3. The stepwise increase in recommended mg/age can be seen in 
the figure, with a range introduced at age 12. Maximum dose recommendation for desmopressin in the 
BNF is higher for all age categories, whereas the AHFS recommends a fixed dose however 
individualized dosing according to needs is advocated. 
Figures 5 – 8 are examples from dosing category 4. Oseltamivir (Figure 6) fluctuates within 
100 – 138mg/m2 range from birth to 15, before steadily dropping to 87.8 mg/m2 at age 17. Cefuroxime 
(Figure 7) shows an abrupt increase in mg/m2 at age 2 before dropping steadily back to the starting 
dose at age 12, where ranges are then introduced. Dosing recommendations for both osetamivir and 
cefuroxime are similar between the AMH-CDC, BNF and AHFS. Voriconazole (Figure 8) linearly 
increases from 400mg/m2 at age 2 to ~550mg/m2 at age 11, before decreasing slightly before a range 
is introduced. Vigabatrin (Figure 9) shows wide ranges from birth equivalent to ~ 2000mg/m2 
differences between the minimum and maximum dose at some points. Dosing recommendations for 
voriconazole and vigabatrin provided in the AMH-CDC are similar to those of BNF. The AHFS 
recommends a fixed dose for all age groups for voriconazole and does not provide a recommendation 
for vigabatrin doses for those under 10 years. 
 
Discussion 
This study aimed to investigate paediatric dosing recommendations in terms of their adherence 
to the BSA scaling principle and the associated inconsistencies or sudden dose transitions across age 
groups. The illustrated drug treatments chosen from the AMH-CDC had dose recommendations that 
were overall similar to recommendations provided by the BNF for children and the AHFS. The drugs 
showed various dosages patterns, some associated with dose disruptions or discontinuities across the 
paediatric age range. Those that allow for quite consistent dosing across the age range are those with 
large dose ranges, though in some cases having such broad therapeutic recommendations can be 
unhelpful in terms of prescribing individualized treatment. 
With a lack of the appropriate pharmacodynamic and pharmacokinetic studies to guide more 
accurate dosing, we considered current dosage guidelines that allows similar physiological 
concentrations across between birth to age 18 (as reflected in the equivalent mg/m2 graph) as the next 
best. It is noteworthy, that only around 2% of drugs in the CDC and 3.4% of the equivalent drugs in the 
BNF were dosed according to BSA. Although, drugs commonly dosed according to BSA such as 
chemotherapy agents, are not commonly listed in the CDC as they are protocol specific. From the 
illustrated drug treatments, the BSA equivalent doses for oseltamivir, dexamethasone and vigabatrin 
best demonstrate opportunity for fairly consistent dosing across children of different age groups.  
Dexamethasone is dosed at a constant mg/kg which corresponds to a BSA dosage which increases 
greater than two-fold between birth to age 18, the acceptable range of dosing would allow fairly 
consistent mg/m2 dosing throughout the age range (Figure 3). Likewise, vigabatrin shows a drug with 
wide ranges from birth which allow consistent mg/m2 dosing, however its minimum and maximum 
doses display inconsistent patterns (Figure 9). Known pharmacokinetic data of vigabatrin (Sabril, 
Sanofi Aventis) in the paediatric population reports a comparison of neonates (age 15-26 days), infants 
(age 5-22 months) and children (age 4.6-14.2 years), showing decreased clearance with age groups, 
however similar renal clearance of children to adults (21). In an early clinical trial, sixty-six children 
aged between 2 and 15 treated with vigabatrin found optimal efficacy between 40 -80 mg/kg/day with 
doses over 100mg/kg/day resulting in no significant adverse events (22), supporting the wide 
therapeutic window reflected in vigabatrin dosing guidelines. Pharmacokinetic modeling has indicated 
that in children 1 – 12 years, a dose of 2mg/kg results in a cumulative dose similar to that which is safe 
and effective in adults (23). A randomized control trial using this dosage was well-tolerated and showed 
efficacy for influenza (23), though this not the recommended dosage in the AMH-CDC (Figure 6).   
Digoxin is an example drug treatment with a very narrow therapeutic range. As can be seen in 
Figure 4 there is much less variability in the BSA dose than the mg/kg dose, highlighting the strength 
of this approach. Yet fixed dosing according to a fixed mg/kg remains the dominant recommendation. 
For other treatments, ranges are available but not until age 12 for example, desmopressin (Figure 5) and 
cefuroxime (Figure 7), which display very similar BSA equivalent dosage patterns despite different 
recommended treatment regimes. Both treatments show inconsistent and disrupted dosage, even when 
ranges are introduced in early adolescence.  
The greatest discontinuities we observed were a result of a switch in dosing guidelines 
between a set dose or a dose based on weight, which commonly occurred between age 12 - 14. The 
Center for Drug Evaluation and Research generally categorizes paediatric age groups into: neonates 
(birth to one month); infants (1 month to two years); children (two – 12 years) and adolescents (12 – 
16). Though in their working guidance for industry document, the Food and Drug Administration 
recognizes these specific age groups do not necessarily need to be used in studies but alternative age 
groupings based on physiology should be scientifically supported (FDA (24)). In the case of weight 
based dosing, there is less variability during infancy and childhood until about the age of 13 when the  
variation of age with weight is highest (25) – which reflects the dosing switches seen across drugs in 
this study. 
Commonly what is seen is dose recommendations based on available drug formulations. For 
example, cefuroxime, one of the example drug treatments with the most inconsistent and disrupted BSA 
equivalent dosing, is one in which the recommendations align with exact multiples of the tablet 
formulation (250mg).  On the other side of the coin, how well clinicians are able to meet the 
recommended oral dosing guidelines are based on the available formulations of the drug. For example, 
treating a typical ~9kg 1-year-old child for central diabetes insipidus with desmopressin (Figure 5) 
according to oral dose recommendations requires 10 µg of the medication twice or three times daily yet 
the medication is only available in tablet formulations of 200 µg. Further, the guidelines commonly 
provided dosages in simple weight based formulas, which are less complicated and as such less prone 
to error that those prescribed according to BSA. Although current technology enables electronic 
calculation and decreases the risk of error. 
The implications of the inconsistent and discontinuous drug recommendations identified in our 
investigation are more important for some drugs than others. With continuing medications such as 
pamidronate, digoxin and vigabatrin requiring a much greater dosing consistency across age groups 
compared to medications with a shorter course length, such as those for infections. That said it is 
important to consider that a 13-year old adolescent with a serious fungal infection would be 
recommended a voriconazole dose of 480 mg/m2 and a child one year older could receive a dose as low 
as 265 mg/m2. It is unknown how, on the population level, that these discontinuous recommendations 
are treated clinically. An analysis of prescribing data would be very useful in that sense, in order to 
utilize real world data to further guide dose recommendations.  
Dose ﬁnding studies in children are difficult (7). Therefore, many drugs used in children do not 
have paediatric labelling information (26). Formularies can be improved by utilizing model-based 
methods to determine optimal paediatric dosage of existing drugs. For example, paediatric models have 
been successfully developed for various drugs including, midazolam, lorazepam, tramadol, 
acetaminophen, and voriconazole (27).  In several countries, new drug development for children 
requires paediatric investigation plans (28, 29) and model based methods for dose optimization are 
required (30). Interest in model-based methods for personalized medicine is increasing, particularly for 
genotype-directed therapy (31). Furthermore, physiology-based pharmacokinetic models have been 
used to evaluate drugs for potential drug–drug interactions (32). Thus, the effect of various dosing 
regimens on interacting drugs can be established and drugs can be individually optimized for 
polytherapy (33). 
 
Conclusion 
Paediatric dosage guidelines appear to be based on simple formulas (such as mg/kg), 
available dosing formulations, and prior patterns of use. Two or more-fold variation from doses that 
would be predicted by allometric scaling are common, as are arbitrary large shifts in recommended 
doses at age thresholds. While doses may be safely approximated for drugs with large therapeutic 
margins, accurate dose estimation for drugs with narrow therapeutic margin is imperative in order to 
minimise the risk of drug toxicity. Drugs used to treat childhood leukaemia are routinely dosed using 
BSA (34, 35), which has contributed to achieving impressive improvement in outcomes in recent 
years (35).   
In absence of pharmacokinetic and pharmacodynamic studies, further research is required to determine 
if better outcomes could be achieved paediatric conditions by adopting biologically based scaling of 
paediatric doses.   
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Table 1. Example drug treatments chosen for investigation 
 
Dosage category 
 
Drug Indication Administration Formulation 
1. Same dose 
recommendation 
for all 
age/weight 
groups 
Dexamethasone Croup Oral/IV/IM Inj, 4mg/ML; 
tab (scored), 
500mcg, 4mg 
2. Change in mg/kg 
dosing according 
to age or weight  
Digoxin Atrial 
tachyarrhythmia 
Oral Tab, 
62.5mcg; tab 
(scored), 250 
mcg 
3. Change in the set 
dose in mg 
according to age 
or weight  
 
Desmopressin Central diabetes 
insipidus 
Oral Tab (scored), 
200mcg 
4. Change from a 
mg/kg dosing 
regimen to a set 
dose in mg 
according to age 
or weight 
Oseltamivir Influenza Oral Cap, 30mg, 
45mg, 75mg 
Cefuroxime Bacterial 
infections 
Oral Tab, 250mg 
Voriconazole Fungal 
infections 
Oral Tab, 50mg, 
200mg 
Vigabatrin Adjunct 
refractory 
partial seizures 
Oral Tab (scored), 
500mg 
Figure 1. Flow diagram of included drug regimens and the relative dosing groups based on 
categorization as follows: Dosing category 1: same dose recommendation in milligrams per kilogram 
(mg/kg) for all age/weight groups; Dosing category 2: change in the mg/kg dosing according to age or 
weight; Dosing category 3: change in the set dose in milligrams (mg) according to age or weight; Dosing 
category 4: Change from a mg/kg dosing regimen to a set dose in mg according to age or weight; Dosing 
category 5: The same dose recommendation for all age or weight groups in mg; Dosing category 6: 
Drugs dosed according to BSA 
 
Figure 2. Line graph representing dosing using allometric principles versus dosing according to mg/kg 
(black dotted line). Doses represented as the percentage of adult dose. Allometric principles shown on 
the graph include body surface area (grey dash), 0.67 exponent model (solid black line) and 0.75 
exponent model (black dashed line).  
 
Figure 3. Recommended daily dosages for dexamethasone (Left: mg, Middle: mg/kg, Right: mg/m2). 
Figure based on oral/intravenous/intramuscular treatment of croup. Shaded areas indicate the range 
for minimum and maximum dose. Equivalent doses calculated from the recommended dose based on 
average weight or body surface area per age group.   
 
Figure 4. Recommended daily dosages for digoxin (Left:mg, Centre: mg/kg, Right: mg/m2). Figure is 
based on oral maintenance treatment of atrial arrhythmia. Shaded areas indicate the range for 
minimum and maximum dose. Equivalent doses calculated from the recommended dose based on 
average weight or body surface area per age group.  
 
Figure 5. Recommended daily dosages for desmopressin (Left:mg, Centre: mg/kg, Right: mg/m2). 
Figure based on oral treatment of central diabetes insipidus, dosed 3 times daily. Shaded areas 
indicate the range for minimum and maximum dose. Equivalent doses calculated from the 
recommended dose based on average weight or body surface area per age group.  
 
Figure 6. Recommended daily dosages for oseltamivir (Left:mg, Centre: mg/kg, Right: mg/m2). Figure 
based on oral oseltamivir treatment dosage of influenza. Shaded areas indicate the range for minimum 
and maximum dose. Equivalent doses calculated from the recommended dose based on average weight 
or body surface area per age group.  
 
Figure 7.  Recommended daily dosages for cefuroxime (Left:mg, Centre: mg/kg, Right: mg/m2). Figure 
is based on oral treatment of bacterial infections. Shaded areas indicate the range for minimum and 
maximum dose. Equivalent doses calculated from the recommended dose based on average weight or 
body surface area per age group.  
 
Figure 8. Recommended daily dosages for voriconazole (Left:mg, Centre: mg/kg, Right: mg/m2). 
Figure based on oral maintenance dosage for treatment of serious fungal infections. Shaded areas 
indicate the range for minimum and maximum dose. Equivalent doses calculated from the 
recommended dose based on average weight or body surface area per age group.  
 
Figure 9. Recommended daily dosages for vigabatrin (Left:mg, Centre: mg/kg, Right: mg/m2). Figure 
based on oral vigabatrin for maintenance treatment of adjunct refractory partial seizures. Shaded areas 
indicate the range for minimum and maximum dose. Equivalent doses calculated from the 
recommended dose based on average weight or body surface area per age group. 
 
 
